The role of estriol in the treatment of atrophy of the mucous membrane of the lower genitourinary tract in postmenopausal women
https://doi.org/10.14341/probl13198
Abstract
Studies of recent decades show a steady increase in the average life expectancy of a person, and women in particular. The World Health Organization predicts a four-fold increase in the number of women over 70 by 2030, and many of them over the age of 45 may face menopausal problems. Menopause is a physiological state in a woman’s life, during which, against the background of age-related changes, there is a gradual decrease and shutdown of ovarian function and the cessation of estrogen production. Genitourinary syndrome occurs in every third woman in this period. Estriol is the main estrogen that specifically addresses problems associated with estrogen deficiency: dyspareunia, dryness and itching in the vagina and lower genitourinary tract, urinary incontinence, moderate urinary incontinence, and recurrent vulvovaginitis and cystitis. Vulvovaginal dystrophy in women of the older age group is a multidisciplinary problem at the intersection of gynecology, urology and dermatology, which can and should be solved to prevent more severe gynecological and urological pathologies.
About the Authors
E. N. Andreeva
Endocrinology Research Centre; Evdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Competing Interests:
Russian Federation
Elena N. Andreeva - MD, PhD, DSc
11 Dm. Ulyanov str., Moscow, 117036
SPIN-код: 1239-2937
Competing Interests:
None
E. V. Sheremetyeva
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Ekaterina V. Sheremetyeva - MD, PhD
11 Dm. Ulyanov str., Moscow, 117036
SPIN-код: 9413-5136
Competing Interests:
None
References
1. Andreeva EN, Sheremetyeva EV. Mental aspects and fat metabolic disturbance in menopause. Obstetrics and gynecology. 2019;(9):165-172. (In Russ.). doi: https://doi.org/10.18565/aig.2019.9.165-172
2. Tkacheva ON, Runikhina NK, Kotovskaia IuV, et al. Metodicheskie rekomendatsii «Profilaktika prezhdevremennogo stareniia u zhenshchin». Moscow: 2018. (In Russ.).
3. Calleja-Agius J, Brincat MP. Urogenital atrophy. Climacteric. 2009;12(4):279-285. doi: https://doi.org/10.1080/13697130902814751
4. Panay N, Palacios S, Bruyniks N, et al. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. Maturitas. 2019;124(4):55-61. doi: https://doi.org/10.1016/j.maturitas.2019.03.013
5. Palacios S, Nappi RE, Bruyniks N, et al. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. 2018;21(3):286-291. doi: https://doi.org/10.1080/13697137.2018.1446930
6. Shifren JL. Genitourinary syndrome of menopause. Clin Obstet Gynecol. 2018;61(3):508-516. doi: https://doi.org/10.1097/GRF.0000000000000380
7. Vieira-Baptista P, Donders G, Margesson L, et al. Diagnosis and management of vulvodynia in postmenopausal women. Maturitas. 2018;(108):84-94. doi: https://doi.org/10.1016/j.maturitas.2017.11.003
8. Calleja-Agius J, Brincat MP. The urogenital system and the menopause. Climacteric. 2015;18(S1):18-22. doi: https://doi.org/10.3109/13697137.2015.1078206
9. Rossiiskoe obshchestvo urologov. Klinicheskie rekomendatsii. Nederzhanie mochi u vzroslykh. Moscow: MZ RF; 2020. (In Russ.).
10. Krychman M, Graham S, Bernick B, et al. The women’s EMPOWER survey: women’s knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate. J Sex Med. 2017;14(3):425-433. doi: https://doi.org/10.1016/j.jsxm.2017.01.011
11. Huang AJ, Gregorich SE, Kuppermann M, et al. Day-to-day impact of vaginal aging questionnaire. Menopause. 2015;22(2):144-154. doi: https://doi.org/10.1097/GME.0000000000000281
12. Angelou K, Grigoriadis T, Diakosavvas M, et al. The genitourinary syndrome of menopause: an overview of the recent data. Cureus. 2020;12(4):e7586. doi: https://doi.org/10.7759/cureus.7586
13. Angelou K, Grigoriadis T, Diakosavvas M, et al. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992. doi: https://doi.org/10.1097/GME.0000000000001609
14. Apolikhina IA, Iureneva SV, Malyshkina DA. Genitourinarnyi menopauzal’nyi sindrom: sovremennye podkhody k diagnostike i lecheniiu. Obstetrics and gynecology. 2020;(12):4-8. (In Russ.).
15. Mension E, Alonso I, Castelo-Branco C. Genitourinary Syndrome of Menopause: Current Treatment Options in Breast Cancer Survivors – Systematic Review. Maturitas. 2021;143(9):47-58. doi: https://doi.org/10.1016/j.maturitas.2020.08.010
16. Li B, Duan H, Chang Y, Wang S. Efficacy and safety of current therapies for genitourinary syndrome of menopause: A Bayesian network analysis of 29 randomized trials and 8311 patients. Pharmacol Res. 2021;164(9):105360. doi: https://doi.org/10.1016/j.phrs.2020.105360
17. Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-150. doi: https://doi.org/10.3109/13697137.2015.1129166
18. Punnonen R, Vilska S, Grönroos M, Rauramo L. The vaginal absorption of oestrogens in postmenopausal women. Maturitas. 1980;2(4):321-326. doi: https://doi.org/10.1016/0378-5122(80)90034-1
19. Reed-Kane D. Natural hormone replacement therapy: What it is and what consumers really want. Int J Pharmaceut Compounding. 2001;5(5):332-335.
20. Khan IU, Serra CA, Anton N, et al. Microfluidic conceived Trojan microcarriers for oral delivery of nanoparticles. Int J Pharm. 2015;493(1-2):7-15. doi: https://doi.org/10.1016/j.ijpharm.2015.06.028
21. Anton N, Jakhmola A, Vandamme TF. Trojan microparticles for drug delivery. Pharmaceutics. 2012;4(1):1-25. doi: https://doi.org/10.3390/pharmaceutics4010001
22. Li X, Anton N, Ta TM, et al. Microencapsulation of nanoemulsions: novel Trojan particles for bioactive lipid molecule delivery. Int J Nanomedicine. 2011;(6):1313-1325. doi: https://doi.org/10.2147/IJN.S20353
23. Prilepskaya VN, Nazarenko EG. Estriol in therapy of various gynecological diseases. Medical Council. 2017;(2):8-13. (In Russ.). doi: https://doi.org/10.21518/2079-701X-2017-2-8-13
24. Vooijs GP, Geurts TBP. Review of the endometrial safety during intravaginal treatment with estriol. Eur J Obstet Gynecol Reprod Biol. 1995;62(1):101-106. doi: https://doi.org/10.1016/0301-2115(95)02170-C
25. Ali ES, Mangold C, Peiris AN. Estriol: emerging clinical benefits. Menopause. 2017;24(9):1081-1085. doi: https://doi.org/10.1097/GME.0000000000000855
26. Capobianco G, Donolo E, Borghero G, et al. Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. Arch Gynecol Obstet. 2012;285(2):397-403. doi: https://doi.org/10.1007/s00404-011-1955-1
27. Lose G, Englev E. Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. BJOG An Int J Obstet Gynaecol. 2000;107(8):1029-1034. doi: https://doi.org/10.1111/j.1471-0528.2000.tb10408.x
28. Федеральный закон от 12.04.2010 N 61-ФЗ (ред. от 14.07.2022) «Об обращении лекарственных средств». Federal Law of Russian Federation 12.04.2010 N 61-FZ (red. ot 14.07.2022) «Ob obrashchenii lekarstvennykh sredstv» (In Russ.).
29. Rossiiskoe obshchestvo akusherov-ginekologov. Klinicheskie rekomendatsii. Menopauza i klimaktericheskoe sostoianie u zhenshchiny. Moscow: MZ RF; 2021. (In Russ.).
30. Lumsden MA, Davies M, Sarri G. Diagnosis and Management of Menopause. JAMA Intern Med. 2016;176(8):1205. doi: https://doi.org/10.1001/jamainternmed.2016.2761
31. Vzaimozameniaemye lekarstvennye preparaty (p. 4 ch. 4 st. 3 Federal’nogo zakona ot 27.12.2019 № 475-FZ, p. 8 postanovleniia Pravitel’stva ot 05.09.2020 № 1360) (In Russ.).
32. Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13(6):509-522. doi: https://doi.org/10.3109/13697137.2010.522875
33. Labrie F, Martel C, Pelletier G. Is vulvovaginal atrophy due to a lack of both estrogens and androgens? Menopause. 2017;24(4):452-461. doi: https://doi.org/10.1097/GME.0000000000000768
34. Vetuschi A, D’Alfonso A, Sferra R, et al. Changes in muscularis propria of anterior vaginal wall in women with pelvic organ prolapse. Eur J Histochem. 2016;60(1):33-38. doi: https://doi.org/10.4081/ejh.2016.2604
35. Donders GGG, Ruban K, Bellen G, Grinceviciene S. Pharmacotherapy for the treatment of vaginal atrophy. Expert Opin Pharmacother. 2019;20(7):821-835. doi: https://doi.org/10.1080/14656566.2019.1574752
36. Traish AM, Vignozzi L, Simon JA, et al. Role of Androgens in Female Genitourinary Tissue Structure and Function: Implications in the Genitourinary Syndrome of Menopause. Sex Med Rev. 2018;6(4):558-571. doi: https://doi.org/10.1016/j.sxmr.2018.03.005
37. Pessina MA, Hoyt RF, Goldstein I, Traish AM. Differential effects of estradiol, progesterone, and testosterone on vaginal structural integrity. Endocrinology. 2006;147(1):61-69. doi: https://doi.org/10.1210/en.2005-0870
38. Berman JR, Almeida FG, Jolin J, et al. Correlation of androgen receptors, aromatase, and 5-α reductase in the human vagina with menopausal status. Fertil Steril. 2003;79(4):925-931. doi: https://doi.org/10.1016/S0015-0282(02)04923-3
39. Labrie F, Derogatis L, Archer DF, et al. Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy. J Sex Med. 2015;12(12):2401-2412. doi: https://doi.org/10.1111/jsm.13045
40. Merritt P, Stangl B, Hirshman E, Verbalis J. Administration of dehydroepiandrosterone (DHEA) increases serum levels of androgens and estrogens but does not enhance short-term memory in post-menopausal women. Brain Res. 2012;(1483):54-62. doi: https://doi.org/10.1016/j.brainres.2012.09.015
41. Labrie F, Martel C, Balser J. Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women. Menopause. 2011;18(1):30-43. doi: https://doi.org/10.1097/gme.0b013e3181e195a6
42. Rossiiskoe obshchestvo akusherov-ginekologov. Klinicheskie rekomendatsii. Vypadenie zhenskikh polovykh organov. Moscow: MZ RF; 2021. (In Russ.).
43. Rossiiskoe obshchestvo urologov. Klinicheskie rekomendatsii. Tsistit u zhenshchin. Moscow: MZ RF; 2021. (In Russ.).
44. Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide Maturitas 2021;148:55-61. Available from: https://emas-online.org/emas-clinical-guides/
45. Griesser H, Skonietzki S, Fischer T, et al. Low dose estriol pessaries for the treatment of vaginal atrophy: A double-blind placebocontrolled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol. Maturitas. 2012;71(4):360-368. doi: https://doi.org/10.1016/j.maturitas.2011.12.022
46. Rueda C, Osorio AM, Avellaneda AC, et al. The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review. Climacteric. 2017;20(4):321-330. doi: https://doi.org/10.1080/13697137.2017.1329291
47. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;2016(11). doi: https://doi.org/10.1002/14651858.CD001500.pub3
Supplementary files
Review
For citations:
Andreeva E.N., Sheremetyeva E.V. The role of estriol in the treatment of atrophy of the mucous membrane of the lower genitourinary tract in postmenopausal women. Problems of Endocrinology. 2022;68(6):157-163. (In Russ.) https://doi.org/10.14341/probl13198
Views:
23612
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
